• Resistance index to erythropoietin
• Haemoglobin level/weekly rHuerythropoietin dose in patients receiving l-carnitine versus those receiving the placebo.

• Acylcarnitine/carnitine ratio measured quarterly
• Number of red blood cells transfusion per patient during the study, data collected monthly
• Predialysis hypotension per patient during the study, data collected monthly
• SF 36 physical and total score at inclusion and at the end of the study
• Lipid profile, measured quarterly
• HbA1c, measured quarterly for diabetic patients and patients with glucose intolerance
• Albuminemia measured quarterly
• c reactive protein measured quarterly

Hemodialysis is a cause of carnitine deficiency. The deficiency of carnitine induces an anemia by an increase fragility of the red blood cells, a muscular fatigue and a cardiac dysfunction. We proposed to evaluate the benefit of an early administration of L-carnitine in hemodialysis patients. The patients should be included in the first month after the start of chronic hemodialysis, randomized to receive L-carnitine or placebo and should be followed-up during one year.

The first aim of the study is to compare the resistance index to erythropoietin (hemoglobin level / rHuerythropoietin dose) with L-carnitine versus placebo Double blind randomized study evaluating the supplementation with L-carnitine versus placebo in patients beginning chronic hemodialysis for less than 1 month.

Primary outcome to compare rHuerythropoietin resistance index defined as hemoglobin level / rHuEPO dose ratio with L-carnitine and with placebo.

Secondary endpoints to compare acylcarnitine / carnitine ratio, number of red blood cells transfusion, physical status, quality of life, hypotensive episodes, lipid profile, diabetes profile, albuminemia, c reactive protein.

Several variables that influenced primary and secondary endpoints will be included in a multivariate analysis; albuminemia, c reactive protein, iron status, dialysis efficiency, protein intake, lipid intake, treatment with additional vitamins (C, B9, B6), treatment with statins, treatment of predialysis hypotension by midodrine, antihypertensive treatments.

Statistical analysis:

• description of the cohort
• comparisons of each evaluated variables between the 2 treatments
• ANOVA study for repeated measurements from inclusion to month-12 for Hb / rHuEPO dose to compare the course of the ratio between each group in intention to treat analysis
• analysis of the ratio Hb / rHuEPO month by month and taking into account tempera withdrawal

Following analysis in both intention to treat and per protocol analysis:

• acylcarnitine / carnitine ratio by ANOVA for repeated data
• number of predialysis hypotension by Chi2 test
• number of red blood cells transfusion by Chi2 test
• SF-36 physical status by comparison of mean
• SF-36 total score by comparison of mean
• lipid profile by ANOVA for repeated data
• HbA1c by ANOVA for repeated data
• variables that influenced primary and secondary variables will be analyzed by multivariate analysis
• statistical study of clinical events per month

• Patient Beginning Chronic Hemodialysis for Less Than 1 Month
• Treated With rHuerythropoietin

Inclusion Criteria:

• Patient with less than 1 month on hemodialysis.
• Treated with rHuEPO.
• Male or female aged of more than 18 years old.
• With contraception treatment for women of procreation age.
• Having received and understand information.

Exclusion Criteria:

• Patients with no need of rHuEPO
• Patients with cancer disease
• Patients with life expectancy under 6 months
• Patients having a proved carnitine deficiency before the start of hemodialysis